The Latest Breaking News on Pharma

Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.

Tweakers reports that several AMD add-in board partners confirmed the upper mid-range RX 7900 GRE is now declared "end-of-life" and is no longer being produced.

AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock.

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock performance. With a clear focus on cancer treatment innovation and a growing market presence, is the company set to lead the future of cancer care and treatment? Read more….

In a New York Times essay, Andrew Witty also says slain healthcare CEO Brian Thompson cared about customers

Consultancy giant agrees to two criminal counts, including for conspiring with drug manufacturers, in DoJ settlement

McKinsey & Company agrees to pay 0 million in settlement for its role in Purdue Pharma's opioid crisis, impacting addiction and overdose prevention efforts.

McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.